Relmada Therapeutics (RLMD) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 27, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by May 26, 2026.

Voting matters and shareholder proposals

• Election of two Class II directors for three-year terms expiring at the 2029 Annual Meeting.

• Ratification of CBIZ CPAs P.C. as independent auditor for the fiscal year ending December 31, 2026.

• Amendment to the 2021 Equity Incentive Plan to increase available shares by 3 million.

• Amendment to Articles of Incorporation to increase authorized common stock from 150 million to 200 million shares.

• Provision to address any other business that may arise at the meeting.

Board of directors and corporate governance

• Nominees for Class II director positions are Charles J. Casamento and Sergio Traversa.